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Cell lines which are infected with retrovirus are resistant to superinfection by a related retrovirus.
Packaging of whole virions within synthetic lipid vesicles allows efficient infection of such resistant cell
lines. This system is more efficient in introducing encapsulated virus into infected cells than into uninfected
cells.
Infection of a permissive cell line with a nondefective
retrovirus yields a cell line which is a chronic producer of
that virus and which is resistant to superinfection by related
retroviruses (interference). Studies of avian leukosis virus
and sarcoma virus infections (21, 25, 26, 29), as well as a
number of mammalian retrovirus systems (11, 22, 23), have
indicated that an endogenously produced viral glycoprotein
binding to surface viral receptors causes the interference (7,
25, 26). Several techniques exist to overcome this block to
superinfection. A different type of viral receptor on the cell
surface can be employed if the virus to be superinfected is
pseudotyped with a nonrelated retrovirus or other animal
virus (4, 31). Alternatively, production of viral glycoprotein
by the infected cell can be transiently blocked by inhibitors
of glycosylation, making some of the cellular virus receptors
available to bind the superinfecting virus (2, 20). Another
option is use of a DNA copy of the retroviral RNA genome
which can be transfected into the chronically infected cell
line.
An alternative and simpler technique to those used previ-
ously would be to package virions (or virion cores) into
synthetic lipid vesicles. Fusion of these vesicles with cellular
membranes might then mediate an infection.
Large, unilamellar lipid vesicles can be prepared in a
number of ways, including calcium-EDTA chelation (18, 27),
ether injection (3, 6), removal of detergents (8, 19), and
reverse-phase evaporation (28). We have found only one of
these methods, reverse-phase evaporation, to be practical
and efficient enough to mediate retrovirus infection. In our
hands, these reverse-evaporation vesicles (REV) are without
any demonstrable toxicity in all cell lines tested, including
the mouse fibroblast lines NIH-3T3, BALB/c-3T3, and L-
cells, a murine lymphocyte line, a mink cell line (CCL-64
[11]), and the human HeLa cell line, even at lipid concentra-
tions as high as 66 ,umol of lipid per ml and >100 ,umol of
lipid per 106 cells. Encapsulation by large, unilamellar vesi-
cles is essentially a passive process, the result of entrapment
of the aqueous phase of an emulsion as the vesicles are
formed (17). The relatively large internal volumes of REV
allow passive entrapment of 40 to 60% of an aqueous
suspension of proteins or nucleic acids (28). To examine
whether we could attain this efficiency, 32P-labeled 28S RNA
was used as a marker, and entrapment was measured by
exclusion chromatography. RNA rather than whole virions
was examined because the large size of the virions makes
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chromatographic separation of free virions from vesicle-
encapsulated virions difficult. About 45% of the input 28S
ribosomal RNA was recovered in vesicles in a typical REV
preparation that incorporated both (unlabeled) retroviral
virions and labeled RNA (Fig. 1). In this case, 45% is an
underestimate of encapsulation because smaller vesicles
would not elute in the void volume of the chromatographic
column.
To examine the biological properties of an REV-encapsu-
lated retrovirus, we used the virus produced by the G8-124
line of Moloney murine sarcoma virus (MSV)-producing
cells (1). The ratio of defective sarcoma virus to the helper
virus, Moloney murine leukemia virus (M-MuLV), in a
typical preparation was 98:2 (15). The focus-forming unit
(FFU) titer on uninfected NIH-3T3 cells for a typical 24-h
harvest from G8-124 ranged from 1 x 106 to 3 x 106 FFU/ml
(Table 1). Because this defective MSV was pseudotyped
with the helper M-MuLV, NIH-3T3 cells which were pro-
ductively infected with M-MuLV and cloned (M-NIH cells)
or which were infected with a defective variant of M-MuLV
so that only the M-MuLV glycoprotein was produced (clone
M-13 cells) would be expected to be resistant to superinfec-
tion with MSV. Table 1 demonstrates a 104-fold decrease in
the FFU titer of an MSV stock on M-NIH cells or M-13
cells.
The titers of different preparations of MSV-containing
REV were determined on each of three cell lines (NIH-3T3,
M-NIH, and M-13). The FFU titer of REV prepared from 1
ml of an MSV stock having a titer of 1 x 106 to 3 x 106
FFU/ml was approximately 2 x 103 FFU/ml on NIH cells.
Although attempts were not made to separate unencapsulat-
ed MSV virions from REV-encapsulated ones, it is doubtful
that any of this focus-forming activity resulted from unen-
capsulated, intact MSV virions because the combined treat-
ment of an organic solvent (diethyl ether) and sonication is
likely to have functionally disrupted the virions. Indeed,
simple active mixing of a stock of MSV with ether, followed
by evaporation of the ether, resulted in complete loss of
focus-forming activity (data not shown). Preparations of
liposomes made without MSV had no focus-forming activity.
When the same preparations of MSV-containing lipo-
somes were tested for their ability to form foci on M-NIH
cells, their FFU titers were substantially increased over
those found on uninfected cells (Table 1). On M-13 cells, the
titers of the liposome preparations were similar to those
found on uninfected NIH-3T3 cells.
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FIG. 1. Encapsulation of macromolecules into liposomes. For-
mation of REV is essentially as described by Szoka and Papahadjo-
poulos (28). We placed 33 ,umol of cholesterol (Sigma Chemical
Co.), 24.6 p.mol of phosphatidylcholine (ex Egg, Calbiochem-Beh-
ring) and 6.6 pmol of phosphatidylglycerol (Sigma) in a flask on a
rotary evaporator, and the solvent (chloroform) was removed under
vacuum. Care was taken throughout the liposome preparation to
keep all lipids under a nitrogen atmosphere. The lipids were
redissolved in 3 ml of redistilled diethyl ether. One milliliter of
phosphate-buffered saline (13.6 mM NaCl, 0.26 mM KCI, 0.8 mM
NaHPO4, 0.14 mM KH2PO4) containing 100 mg of yeast tRNA
(Sigma) as carrier and MSV virions was added to the lipid-ether
solution. In one preparation, this aqueous phase also contained
tracer amounts of 'P-labeled 28S ribosomal RNA. The two phases
were sonicated in a bath-type sonicator at 0°C for 60 s, by which
time a stable, milky dispersion had formed. The mixture was then
placed on a rotary evaporator, and the ether was removed under
vacuum at 25°C. After 5 min, an additional 2 ml of phosphate-
buffered saline was occasionally added to facilitate suspension of the
vesicles. Evaporation was continued for 30 min to ensure removal of
all traces of the ether. In one preparation of REV, tracer amounts of
32P-labeled 28S RNA were added at this point to monitor nonspecif-
ic adhesion of RNA to preformed REV. One milliliter of the vesicle
preparations was then chromatographed over a 25-ml-bed-volume
Bio-Gel A15 column, with phosphate-buffered saline as the buffer,
to allow separation of vesicles and unencapsulated RNA. Fractions
of 1 ml were collected, and the radioactivity was quantitated by
Cerenkov counting. REV eluted in the void volume. All manipula-
tions involving retroviruses were performed in closed containers or
in laminar flow hoods which emit only filtered air. Symbols: 0,
elution pattern of 28S RNA added before REV formation; 0,
pattern of 28S RNA added to a preformed REV preparation.
Over many years, it has proved difficult to devise a
method for concentrating a stock of retrovirus that preserves
the biological activity of the virions. The usual concentration
techniques involving centrifugation or ultrafiltration appear
to damage the virions, possibly by stripping away glycopro-
tein from the viral membrane and rendering the virions
noninfectious. Typically, after concentration procedures, no
increase or even a decrease in viral titer is observed. For
instance, a stock of MSV with an initial titer of 3 x 106
FFU/ml, after a 10-fold physical concentration (pelleting of
virions from 10 ml of stock and resuspension in 1 ml), can
produce a stock with a titer of only 3 x 103 FFU/ml (Table
1). When 1 ml of this physically concentrated virus was
encapsulated into REV, however, the biological titer of the
virus stock was increased up to eightfold on both infected
and uninfected cells.
REV can be prepared sterilely so that the vesicles can be
immediately applied to cells in culture. To remove bacteria
and fungi from an REV preparation which has not been
prepared sterilely, however, an REV preparation was fil-
tered through a membrane filter (pore size, 0.8 or 0.45 pLm)
by using vacuum rather than pressure. Only a three- to
fourfold loss of activity of an REV preparation was seen
after filtration (Table 1). The combination of filter steriliza-
TABLE 1. Titers of virus and REV
Titer (FFU/ml) on cell line:
Virus preparation
NIH M-NIH" M-13"
MSV stock'
No. 1 1 x 106 2 x 102 1 x 102
No. 2 3 x106 4x102 1 x 10
REV preparation"
No. 1 2.1 x 103 2.7 x 104 1 X 104
No. 2 1.8 x 103 3 x 104 7 x 103
Concentrated (10-fold) 3 X NT' NTMSV stock"
Concentrated (10-fold)
MSV stock in REW
No. 1 8 x 103 1 x 105 2 x 104
No. 2 1.2 x 104 2 x 105 1 x 104
REV preparation after
filtration"
No. 1 9 x 102 6 x 103 NT
No. 2 1.5 x 103 1.2 x 104 NT
"Contact-inhibited clonal line of NIH-3T3 fibroblasts which have
been chronically infected with M-MuLV clone 1 (9).b Cloned cell line described by Shields et al. (24) which contains a
defective M-MuLV provirus. It produces viral glycoprotein (gp7O),
but no infectious progeny virus, and does not appear to produce
reverse transcriptase. It has previously been shown resistant to
superinfection by MuLV and M-MuLV pseudotyped vesicular sto-
matitis virus.
' MSV stocks were titrated as follows. Cells were plated out at a
density of 2 x 105 cells per 60-mm dish on the day before infection.
All cell lines were carried in Dulbecco modified Eagle essential
medium-10% calf serum. On day 0, 0.4 ml of serial 10-fold dilutions
of MSV stocks were added to each plate in the presence of 8 p.g of
polybrene (Sigma) per ml of medium. The infection was continued
for 1 h at 37°C with periodic rocking of the plates. The medium was
then changed, and the cells were refed every 3 days until day 12, at
which time foci were scored. All assays were performed in tripli-
cate.
" Two representative preparations of REV prepared from MSV
stocks 1 and 2, respectively. One milliliter of virus stock yielded 1
ml of liposomes. After preparation of the REV as described in the
legend to Fig. 1, 1 ml of the REV suspension was added to a 60-mm
dish containing 5 ml of medium and 2 x 105 cells plated out the day
before. Cells were exposed to the REV suspension for 2 h at 37°C,
after which the medium was changed. Cells were refed every 3 days,
and foci were scored on day 12. Exposure of cells to REV prepared
in the absence of MSV resulted in no foci.
" Virion stocks were physically concentrated by pelleting of the
virus (centrifugation at 100,000 x g for 2 h at 4°C) and resuspension
in 1/10 of their initial volumes. One milliliter of this volume was then
titrated or used to make 1 ml of an REV preparation.
'NT, Not tested.
REV prepared from the concentrated MSV stocks described
above.
" REV preparations 1 and 2, after filtration under vacuum through
an 0.8-p.m-pore-size filter.
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tion and the use of antibiotics in the tissue culture medium
has been completely effective in preventing contamination of
cell cultures after exposure to REV.
This technique for introducing retrovirus into cells is a
useful method for overcoming the barrier to superinfection
in cells already infected with retrovirus. Encapsulation of a
picornavirus in small, unilamellar vesicles with retention of
biological activity has previously been described (30). Trans-
fection studies have shown, however, that all that is required
for the initiation of picornavirus infection is entry of the
RNA genome into the cell cytoplasm (13, 14). Infection by a
retrovirus, on the other hand, requires at least the presence
of an active reverse transcriptase in addition to an intact
dimeric RNA genome and tRNA primer and perhaps other
interactions between virion proteins and the viral genome.
Retroviral genomic RNA alone is not infectious (12).
It would appear, then, that despite the functional disrup-
tion of the virions in the course of REV preparation,
sufficient amounts of reverse transcriptase and genomic
RNA (and perhaps other required proteins) remain together
to allow synthesis of a provirus upon entry into a cell. In our
hands, other techniques of liposome preparation, including
removal of detergents (8) and calcium-EDTA chelation (18),
appear too damaging to virions because, despite relatively
efficient encapsulation, no biological activity would be re-
covered from MSV virions packaged in those ways.
Physical disruption may account for part or all of the loss
of titer on uninfected cells of MSV stocks after packaging
into REV. In addition to physical damage of virions, other
reasons for the loss of titer can be suggested. The reverse
transcriptase, for instance, may be adversely affected by the
organic solvent employed in REV preparation. The effects of
sonication on the integrity of the genomic RNA molecule
could be implicated in the loss of biological titer, but there is
reason to believe that this effect probably is not a major
problem, because poliovirus RNA, which is approximately
the same size as retroviral genomic RNA (9,000 bases), can
be introduced into cells via REV with a specific infectivity
per microgram of RNA comparable to that achieved by other
transfection techniques (30; unpublished observations).
The efficiency of this system for introduction of a second
retrovirus into infected cells is high (102 to i03 enhancement
with concentrated virions), rivaling that reported when gly-
cosylation inhibitors are used to allow superinfection (20),
but without the toxicity found with these inhibitors. Nearly
every cell (90 to 95%) which is exposed to MSV in REV can
be infected, as assayed by transformation of cellular clones
derived from limiting dilution after treatment with MSV in
REV. Increasing the concentration of vesicles above
33 pLmol of lipid per 105 cells does not result in higher FFU
titers. This is not surprising, in that this concentration
greatly exceeds the level of saturation (100 nmol per 106
cells) calculated by other workers (5). Treatment of cell lines
with glycerol (30) or polyethylene glycol (10) after exposure
to REV did not result in any consistent increase in FFU titer
(data not shown).
The reason that encapsulated MSV interacts more effi-
ciently with cells producing M-MuLV than it does with
uninfected cells is not readily apparent. It is possible that the
infected cells contain enough active reverse transcriptase to
enhance provirus formation from introduced MSV genomic
RNA. The fact that the titer of the MSV REV was not
markedly elevated on M-13 cells, which do not produce an
active reverse transcriptase (24), appears to support this
hypothesis. However, other studies (16, 32) indicate that a
large proportion of the reverse transcriptase in infected cells
is in an inactive precursor form and only becomes activated
upon budding of the virion.
In addition to introducing retroviruses into cells whose
viral receptors are blocked by endogenous virus production,
this system of REV encapsulation should prove useful in
permitting entry of retrovirus into cells that lack viral
receptors. Studies are now under way which explore the use
of recombinant retroviral genomes packaged in virions and
recombinant lambda viral genomes packaged in phage heads
and then encapsulated within REV to mediate gene transfer
into murine T-lymphocyte cell lines (which appear to lack
retrovirus receptors) and into nonmurine cells.
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